Certara sells biosimulation software and scientific services to the global biopharmaceutical and biotech industry. The core idea is that drug development is expensive and failure-prone, and Certara's tools let developers run virtual experiments and clinical trial simulations to predict how drugs behave in the human body — helping them optimize dosing, reduce the number of actual clinical trials, and improve the odds of regulatory approval. Certara's flagship products include Simcyp (a mechanistic biosimulation platform for predicting drug behavior in specific populations), Phoenix PK/PD (the industry-standard tool for pharmacokinetic and pharmacodynamic data analysis), Pinnacle 21 (a cloud-based clinical data standardization tool used by pharma companies and regulators alike), and Chemaxon (scientific informatics tools for drug discovery, acquired in 2024). Certara also offers technology-enabled services where its own scientists use these tools to run analyses, build pharmacometric models, and prepare regulatory submissions on behalf of customers. Revenue splits roughly 40% software and 60% services, with software carrying higher margins and growing recurring subscription revenue. The two streams are synergistic — service engagements introduce customers to software, and as customers mature in their use of biosimulation, they tend to expand software adoption independently. Certara is pushing its platform toward the cloud, integrating AI tools into regulatory writing and model-building, and expanding into earlier drug discovery stages, aided by regulatory tailwinds around reducing animal testing.